Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C.

Invest New Drugs. 2012 Feb;30(1):387-94. doi: 10.1007/s10637-010-9532-1. Epub 2010 Sep 14.

2.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J.

Br J Haematol. 2013 Mar;160(5):649-59. doi: 10.1111/bjh.12198. Epub 2013 Jan 7.

PMID:
23293914
3.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL.

Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18. Erratum in: Lancet Oncol. 2011 Jun;12(6):522.

PMID:
21507715
4.

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.

Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA.

Clin Cancer Res. 2005 May 1;11(9):3410-6.

5.

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.

Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L.

Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.

6.

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM.

J Clin Oncol. 2004 Jan 1;22(1):115-9.

7.

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

Li T, Ho L, Piperdi B, Elrafei T, Camacho FJ, Rigas JR, Perez-Soler R, Gucalp R.

Lung Cancer. 2010 Apr;68(1):89-93. doi: 10.1016/j.lungcan.2009.05.009. Epub 2009 Jun 12.

PMID:
19524318
8.

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.

Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP.

Cancer. 2013 Jan 15;119(2):380-7. doi: 10.1002/cncr.27758. Epub 2012 Jul 25.

9.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.

N Engl J Med. 2003 Jun 26;348(26):2609-17.

10.

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.

Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA.

Cancer Chemother Pharmacol. 2007 Feb;59(2):207-15. Epub 2006 Jun 9.

PMID:
16763792
11.

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ; Cancer and Leukemia Group B.

Ann Oncol. 2008 May;19(5):946-50. doi: 10.1093/annonc/mdm600. Epub 2008 Feb 13.

12.

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.

McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ.

Cancer. 2015 May 15;121(10):1620-7. doi: 10.1002/cncr.29227. Epub 2015 Jan 6.

13.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM.

J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21.

14.

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP.

Invest New Drugs. 2011 Dec;29(6):1475-81. doi: 10.1007/s10637-010-9474-7. Epub 2010 Jun 25.

PMID:
20574790
15.

A phase II study of bortezomib in the treatment of metastatic malignant melanoma.

Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.

Cancer. 2005 Jun 15;103(12):2584-9.

16.

Pharmacology, pharmacokinetics, and practical applications of bortezomib.

Schwartz R, Davidson T.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21. Review.

17.

Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.

[No authors listed]

Prescrire Int. 2006 Jun;15(83):98-100.

PMID:
16764098
18.

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.

Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6111-8.

19.

Bortezomib for multiple myeloma.

Popat R, Joel S, Oakervee H, Cavenagh J.

Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. Review.

PMID:
16805719
20.

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.

Cancer. 2006 Sep 1;107(5):916-24.

Items per page

Supplemental Content

Write to the Help Desk